After 56 months: 32% reduction in the risk of death with DRd vs Rd alone in the MAIA trial (HR=0.68; 95% CI: 0.53, 0.86; P=0.0013; mOS not reached in either arm).*1

Continuous treatment icon

Keep patients on a proven path with frontline DARZALEX® + Rd for newly diagnosed, transplant-ineligible multiple myeloma1

Checklist icon

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for regimens containing daratumumab (DARZALEX®)

Syringe icon

Administration options include ~3 to 5 minute subcutaneous DARZALEX FASPRO® and intravenous DARZALEX®†1,2

*Median follow-up was 56.6 months in the DRd group (IQR: 53.0-60.1 months) and 55.9 months in the Rd group (IQR: 52.5-59.4 months).3

DARZALEX FASPRO® is administered by subcutaneous injection over approximately 3 to 5 minutes. In contrast, DARZALEX® is administered by intravenous infusion over approximately 7, 4, and 3 hours for first, second, and subsequent infusions, respectively.1,2 View IV administration

Cytogenetic risk was based on fluorescence in situ hybridization (FISH) or karyotype analysis. High-risk cytogenetics were defined as having at least one of the following abnormalities: t[4;14], t[14;16], del[17p], t[14;20], gain[1q21], amp[1q21].4

Advancing frontline knowledge: KOL expert series

Watch multiple myeloma experts provide their perspectives on treating newly diagnosed, transplant-ineligible multiple myeloma

Patient considerations when determining frontline treatment

Dr. Kenneth Shain, Director of the Myeloma Working Group at Moffitt Cancer Center (Tampa, Florida), discusses a typical patient seen in his practice and how he reviews safety and efficacy data along with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) when choosing a frontline treatment option.

MAIA study on frontline treatment with DARZALEX® + Rd vs Rd alone, including primary results, and post hoc analysis in frail patients

Dr. Ruemu Birhiray, the founder of Indy Hematology Review, explores safety and efficacy data of the MAIA trial, including a post hoc analysis in frail patients.

MAIA study of patients on frontline triplet DARZALEX® + Rd vs Rd alone, along with high-risk subgroup analysis

Dr. Kenneth Shain reviews the efficacy and safety of DRd vs Rd from the MAIA trial, including a subgroup analysis in patients with a high-risk cytogenetic profile.

CI=confidence interval; DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); HR=hazard ratio; IQR=interquartile range; IV=intravenous; KOL=key opinion leader; MM=multiple myeloma; mOS=median overall survival; NCCN=National Comprehensive Cancer Network; OS=overall survival; Rd=lenalidomide (R) + dexamethasone (d); sub-Q=subcutaneous.


  1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596.
  4. Moreau P, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 MAIA study. Poster presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA.